Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Total Non-Current Liabilities (2016 - 2022)

Spero Therapeutics (SPRO) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $48.9 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Total Non-Current Liabilities fell 40.39% year-over-year to $48.9 million, compared with a TTM value of $48.9 million through Dec 2022, down 40.39%, and an annual FY2022 reading of $48.9 million, down 40.39% over the prior year.
  • Total Non-Current Liabilities was $48.9 million for Q4 2022 at Spero Therapeutics, up from $31.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $82.4 million in Q1 2022 and bottomed at $6.7 million in Q2 2018.
  • Average Total Non-Current Liabilities over 5 years is $33.0 million, with a median of $27.3 million recorded in 2020.
  • The sharpest move saw Total Non-Current Liabilities soared 3450.5% in 2018, then plummeted 40.39% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $12.9 million in 2018, then soared by 49.1% to $19.3 million in 2019, then surged by 41.46% to $27.3 million in 2020, then soared by 200.66% to $82.0 million in 2021, then tumbled by 40.39% to $48.9 million in 2022.
  • Business Quant data shows Total Non-Current Liabilities for SPRO at $48.9 million in Q4 2022, $31.9 million in Q3 2022, and $27.6 million in Q2 2022.